Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series by Faouzi Djebbari, Matt Poynton, Gina Sangha, Laura Anderson, Rebecca Maddams, Toby A. Eyre, Grant Vallance, Supratik Basu, Karthik Ramasamy

Subjects: Get full text

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment by Sonia Morè, Maria Teresa Petrucci, Laura Corvatta, Francesca Fazio, Massimo Offidani, Attilio Olivieri

Subjects: Get full text

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study by Faouzi Djebbari, Alexandros Rampotas, Grant Vallance, Fotios Panitsas, Nanda Basker, Gina Sangha, Beena Salhan, Farheen Karim, Al-Kaisi Firas, Amy Gudger, Loretta Ngu, Matt Poynton, Ho Pui Jeff Lam, Lowri Morgan, Laura Yang, Jennifer Young, Mairi Walker, Ismini Tsagkaraki, Laura Anderson, Saleena Rani Chauhan, Rebecca Maddams, Richard Soutar, Margarita Triantafillou, Steve Prideaux, Abubaker Obeidalla, Toby A. Eyre, Ceri Bygrave, Supratik Basu, Karthik Ramasamy

Subjects: Get full text

CD38‐Specific Gallium‐68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET by Ajay Kumar Sharma, Kuldeep Gupta, Akhilesh Mishra, Gabriela Lofland, Ian Marsh, Dhiraj Kumar, Gabriel Ghiaur, Philip Imus, Steven P. Rowe, Robert F. Hobbs, Christian B. Gocke, Sridhar Nimmagadda

Subjects: Get full text

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies by Guido Lancman, Suzanne Arinsburg, Jeffrey Jhang, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Joshua Richter, Ajai Chari

Subjects: Get full text

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cel... by Hongjie Wang, Theo Koob, Jonathan R. Fromm, Ajay Gopal, Darrick Carter, André Lieber

Subjects: Get full text

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from th... by Joseph Kauer, Emma P. Freundt, Anita Schmitt, Niels Weinhold, Elias K. Mai, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc S. Raab, Katharina Kriegsmann, Sandra Sauer

Subjects: Get full text

Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma by Chantal Reina-Ortiz, David Giraldos, Gemma Azaceta, Luis Palomera, Isabel Marzo, Javier Naval, Martín Villalba, Alberto Anel

Subjects: Get full text

Treatment of double-refractory multiple myeloma by S. V. Semochkin

Subjects: Get full text

Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials by Muhammed Favas Karimbanathottathil, Beema T Yoosuf, M Mamatha, Dipika Bansal

Subjects: “…Isatuximab…”
Get full text

Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg by Sigrid De Wilde, Laurent Plawny, Guy Berchem

Subjects: Get full text

Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiency by F. Jakobs, P. Ahmadi, V. Osterkamp, J. Jeck, U. Holtick, C. Scheid, Florian Kron

Subjects: Get full text

First clinical experience of isatuximab safety and tolerability in relapsed and refractory multiple myeloma: real-world data from a compassionate use program in Germany by Theo Leitner, Cyrus Khandanpour, Cyrus Khandanpour, Knut Wendelin, Fuat Oduncu, Christoph Kimmich, Ralph Naumann, Miriam Kull, Hartmut Goldschmidt, Martin Ehmer, Claudia Kiewitz, Hans Salwender

Subjects: “…isatuximab…”
Get full text

Isatuximab, pomalidomide and dexamethasone in the treatment of relapsed/refractory multiple myeloma in real clinical practice by Vadim V. Ptushkin, Yulia В. Kochkareva, Ekaterina А. Sukhova, Eugene A. Nikitin

Subjects: Get full text

Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia by M. V. Solovev, M. V. Solovevа, L. P. Mendeleeva, T. I. Pospelova, N. V. Skvortsova, A. D. Garifullin, A. S. Chuprakova, T. A. Mitina, I. S. Usankin, I. V. Vasileva, N. V. Medvedeva, V. V. Ryabchikova, M. Ya. Kiseleva, G. A. Dudina, Yu. S. Gammershmidt, O. S. Kuznetsova, Yu. V. Dolgushina, G. B. Kuchma, T. N. Tsyganok, E. N. Misyurina, E. I. Zhelnova, A. V. Kopylova, M. N. Zakharova, A. V. Korobkin, G. S. Tumyan, A. A. Semenova, E. G. Kirillova, E. M. Volodicheva, V. I. Bakhtina, T. I. Olkhovik, N. R. Solovkova, M. V. Demchenkova, O. E. Ochirova, O. L. Panteleeva, V. S. Abramova

Subjects: “…monoclonal antibody isatuximab…”
Get full text

Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review by Flavia Bigi, Enrica Manzato, Simona Barbato, Marco Talarico, Michele Puppi, Simone Masci, Ilaria Sacchetti, Roberta Restuccia, Miriam Iezza, Ilaria Rizzello, Chiara Sartor, Katia Mancuso, Lucia Pantani, Paola Tacchetti, Michele Cavo, Elena Zamagni

Subjects: Get full text

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma by Kamlesh Bisht, Taro Fukao, Marielle Chiron, Paul Richardson, Djordje Atanackovic, Eduardo Chini, Wee Joo Chng, Helgi Van De Velde, Fabio Malavasi

Subjects: Get full text

Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report by Yu. E. Ryabukhina, P. A. Zeynalova, F. M. Abbasbeyli, O. L. Timofeeva, T. T. Valiev, N. A. Kupryshina, A. G. Zhukov

Subjects: Get full text

Anti CD38 monoclonal antibodies for multiple myeloma treatment by Alessandro Gozzetti, Sara Ciofini, Martina Simoncelli, Adele Santoni, Paola Pacelli, Donatella Raspadori, Monica Bocchia

Subjects: Get full text

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma by Joshua Richter, Peggy L. Lin, Viviana Garcia‐Horton, Patricia Guyot, Erin Singh, Zheng‐Yi Zhou, Mark Sievert, Riley Taiji

Subjects: Get full text